In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Academic Article uri icon

Overview

abstract

  • Adoptive transfer therapy of in vitro-expanded tumor-specific cytolytic T lymphocytes (CTLs) can mediate objective cancer regression in patients. Yet, technical limitations hamper precise monitoring of posttherapy T cell responses. Here we show in a mouse model that fused single photon emission computed tomography and x-ray computed tomography allows quantitative whole-body imaging of (111)In-oxine-labeled CTLs at tumor sites. Assessment of CTL localization is rapid, noninvasive, three-dimensional, and can be repeated for longitudinal analyses. We compared the effects of lymphodepletion before adoptive transfer on CTL recruitment and report that combined treatment increased intratumoral delivery of CTLs and improved antitumor efficacy. Because (111)In-oxine is a Food and Drug Administration-approved clinical agent, and human SPECT-CT systems are available, this approach should be clinically translatable, insofar as it may assess the efficacy of immunization procedures in individual patients and lead to development of more effective therapies.

publication date

  • July 18, 2007

Research

keywords

  • Adoptive Transfer
  • Immunotherapy, Adoptive
  • Neoplasms
  • T-Lymphocytes

Identity

PubMed Central ID

  • PMC1941490

Scopus Document Identifier

  • 34547636355

Digital Object Identifier (DOI)

  • 10.1073/pnas.0704460104

PubMed ID

  • 17640914

Additional Document Info

volume

  • 104

issue

  • 30